<DOC>
	<DOCNO>NCT01867021</DOCNO>
	<brief_summary>Demonstrate non-inferiority post-vaccination ( Day 22 ) Hemagglutination inhibition ( HI ) Geometric Mean Titers ( GMTs ) trivalent , inactivate , subunit influenza vaccine ( TIV ) correspond GMTs comparator vaccine three strain , healthy adult age 50 year . Demonstrate non-inferiority percentage subject achieve seroconversion antibody titer Day 22 TIV group correspond percentage subject comparator group three strain , healthy adult age 50 year .</brief_summary>
	<brief_title>Immunogenicity , Safety Tolerability Trivalent Subunit Inactivated Vaccine Healthy Subjects 50 Years Above</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males female age 50 year , mentally competent , willing able give write informed consent prior study entry nature study explain accord local regulatory requirement . Individuals able comply study requirement . Individuals good health determine outcome medical history , physical examination clinical judgment investigator . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study . Individuals progressive severe neurologic disorder , seizure disorder GuillainBarré syndrome . Individuals able comprehend follow require study procedure whole period study . Individuals receive seasonal pandemic influenza vaccine laboratory confirm seasonal pandemic influenza disease within past 6 month . Individuals history illness , opinion investigator , might interfere result study pose additional risk subject due participation study . Individuals positive HIV test result , history autoimmune disorder know suspected impairment /alteration immune system , immunosuppressive therapy within 6 month use parenteral oral corticosteroid within previous 30 day . Individuals know bleed diathesis , condition may associate prolonged bleeding time . Individuals serious chronic progressive disease accord judgment investigator ( neoplasm , insulin dependent diabetes , cardiac , renal hepatic disease ) . Individuals malignancy ( exclude nonmelanotic skin cancer ) lymphoproliferative disorder . Individuals history anaphylactic adverse event and/or serious allergic adverse event follow vaccination , proven hypersensitivity component study vaccine ( eg , egg egg product well ovalbumin , chicken protein , chicken feather , influenza viral protein , kanamycin neomycin sulphate ) latex allergy . Individuals participate clinical trial another investigational product 30 day prior first study visit intent participate another clinical study time conduct study . Receipt nonstudy vaccine ( exception postexposure vaccination medical emergency , eg , hepatitis , rabies , tetanus ) within 3 week prior Visit 1 . Individuals ever receive blood , blood product and/or plasma derivative parenteral immunoglobulin preparation past 12 week . Individuals receive antibiotic within 6 day vaccination . Individuals body temperature ( axillary temperature ) ≥38 degree Celsius ( ≥ 100.4° F ) within last 3 day intend study vaccination . BMI &gt; 35 kg/m2 . Female pregnant nursing ( breastfeed ) mother females childbearing potential plan use acceptable birth control measure , whole duration study . Adequate contraception define hormonal ( eg , oral , injection , transdermal patch , implant , cervical ring ) , barrier ( eg , condom spermicide diaphragm spermicide ) , intrauterine device ( IUD ) , monogamous relationship vasectomize partner vasectomize 6 month prior subject 's study entry ; Abstinence . Individuals part study personnel close family member conduct study . Individuals history substance alcohol abuse within past 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Trivalent inactivate subunit influenza vaccine</keyword>
	<keyword>50 year</keyword>
	<keyword>healthy subject</keyword>
</DOC>